Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition

Tempest Therapeutics, Inc.

Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.
Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.
TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.
Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-130480
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2026-03-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.391080+00:00
generated_at: 2026-05-15T08:23:08.129101+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-130480
json_url: https://secwatch.observer/filing/0001193125-26-130480.json
markdown_url: https://secwatch.observer/filing/0001193125-26-130480.md
text_url: https://secwatch.observer/filing/0001193125-26-130480.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/0001193125-26-130480-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/tpst-20260330.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-130480

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.